Indian FDA Approves the First Immuno-oncology Product, APCEDEN®

NEW YORK, April 5, 2017 /PRNewswire/ -- A first-of-its-kind Indian biotechnology company, APAC Biotech, was granted with a commercial license by Indian FDA (CDSCO - Central Drugs Standard Control Organization) to market product, APCEDEN®, a Dendritic cell-based autologous Immuno-oncology product for four cancer indication namely Prostate, Ovarian, Colo-rectal and Non Small Cell Lung carcinoma. The Indian Food and Drug Administration authorities, after their stringent review of the application, have issued the commercial license (Form 46) to conduct a post marketing surveillance on statistically significant number of patients for each indication. Other products namely STEMPEUCEL®, an allogeneic-cultured mesenchymal cells from Stempeutics and OSSORON®, an autologous-cultured adult osteoblast and CHONDRON®, an autologous-cultured adult chondrocyte from Regenerative Medical Services, Mumbai, also received the marketing license at the same time. "The past decades have seen revolutionary progress in the development and application of cell and genetic engineering in an effort to personalize the treatment of cancer. We are now confident that it is possible to treat cancer patients using this approach as observed during clinical trials across India. The results are encouraging and mark a potential new paradigm in treating these solid tumors that do not respond to standard therapies," said a leading oncologist, Dr. Ashok Vaid.

Read more...
 

DENDRITIC CELL IMMUNOTHERAPY FOR CANCER TREATMENT

APAC BIOTECH strives to find the roots of cancer - the world's alarming disease, by transforming the promise of biotechnology into therapies that have the power to restore health and even save lives of cancer patients. We are providing Dendritic cell based Immunotherapy for the treatment of cancer. We are focused primarily on the research of customised autologous cell based immunotherapy for cancer treatment in India.

colorectal cancer

COLORECTAL CANCER

Most Colon Cancer Deaths can be avoided if everyone was screened regularly.

lung cancer

NSC LUNG CANCER

One day Lung Cancer will be a thing from the past.

ovarian cancer

OVARIAN CARCINOMA

Most women with ovarian cancer develop resistance to chemotherapy drugs.

PROSTATE CANCERprostate cancer

Frequency of prostate cancer in men will increase.

About APAC Biotech

APAC Biotech Pvt. Ltd. is a leading biotechnology company in India involved in research and manufacturing of Dendritic cell based immunotherapy for the treatment of cancer. Our endeavour is to improve the life expectancy of cancer patients by providing safe and effective personalised cell based immunotherapy. Our product APCEDEN® has been developed after a thorough research based on the principles of Immunology.

cancer treatment

apac website

We are APAC Biotech

APAC BIOTECH strives to find roots of cancer - the world's alarming disease, by transforming the promise of technology and knowledge of biology into therapies that have the power to restore health and even save lives of cancer patients.

apac website

Our Technology

Dendritic Cells are antigen presenting cells and have high level of major histocompatibility complex, costimulatory molecules and cell adhesion molecules which are essential for antigen presentation.

R & D

APAC BIOTECH carefully designs its' research study projects that determine the effectiveness of the cancer therapy, under the supervision of highly qualified professional investigators.

Apac Biotech has a group of Qualified Researchers and doctors for Cancer Research & Development activities. We have a 1000 class clean room facility, with state of art equipment. The driving force behind our research team is to constantly improve the qualityquality of life of cancer patients in India.

Our Vision

To find the roots of cancer and to improve the quality of life by immunology based Dendritic cell based therapy.

Who we are?

APAC Biotech Pvt.Ltd. is a leading biotechnology company which is involved research and manufacturing of Dendritic cell based immunotherapy in India and preparing the formulation to impede the growth of cancer cells.

Our endeavour is to improve the life expectancy by providing safe and effective dendritic cell based immunotherapy for treatment of cancer patients. Our formulation, APCEDEN® has been developed in India after a thorough research based on the principles of immunotherapy.

Our Team

ARUN MEHRA-Chief Executive Officer

Arun Mehra is a visionary entrepreneur, responsible for developing dendritic cell immunotherapy at a commercial scale in India.

Have a question or need to Contact?

Apac Biotech Pvt Ltd.

69, Jacranda Marg , DLF PHASE II. GURGAON, INDIA.
Mob: +91- 9958000827 Tel: 0124-4207575
Email: info@apacbiotech.com
Website : www.apacbiotech.com